Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

101. Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells Full Text available with Trip Pro

Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells Long non-coding RNAs (lncRNAs) have been found to show important regulatory roles in various human cancers. Lnc-RNA PANDAR is a novel identified lncRNA that was previously reported to show abnormal expression pattern in various cancers. However, little is known of its expression and biological function in thyroid cancer. Here, we used the quantitative real-time PCR (qRT-PCR (...) ) to determine the expression of PANDAR in 64 thyroid cancer tissues. We found that expression of PANDAR was up-regulated in thyroid cancer tissues compared with adjacent non-tumor tissues. Functional assays in vitro demonstrated that knockdown of PANDAR could inhibit proliferation, cell cycle progression, induces the apoptosis, inhibit invasion of thyroid cancer cells. Thus, our study provides evidence that PANDAR may function as a potential target for treatment for patients with thyroid cancer.

2017 EXCLI journal

102. Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer Full Text available with Trip Pro

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer This image illustrates a multimodal therapeutic strategy for an iodine-refractory BRAF-mutated metastatic papillary thyroid carcinoma with reversed radioiodine resistance using BRAF inhibitors.

2017 Journal of the Endocrine Society

103. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment. Full Text available with Trip Pro

Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment.  To estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism. Retrospective cohort study. Large US administrative database between 1 January 2010 and 31 December 2014. 5405 pregnant women with subclinical hypothyroidism, defined as untreated thyroid stimulating hormone (TSH) concentration 2.5-10 mIU/L. Thyroid hormone therapy (...) . Pregnancy loss and other pre-specified maternal and fetal pregnancy related adverse outcomes. Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment TSH concentration of 4.8 (SD 1.7) mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 (SD 0.9) mIU/L were not treated (P<0.01). Pregnancy loss was significantly less common among treated women (n=89; 10.6%) than among untreated women (n=614; 13.5%) (P<0.01). Compared

2017 BMJ

104. Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up Full Text available with Trip Pro

Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up Trends toward more conservative management of papillary thyroid cancer (PTC) diminish the primacy of serum thyroglobulin (Tg) assays as a posttreatment surveillance tool.To identify thyroid tumor-associated microRNAs (miRNAs) in the serum with potential for development as unique biomarkers of PTC recurrence.We measured expression of 754 miRNAs in serum samples collected from 11 (...) patients with PTC before and 30 days after thyroidectomy. Major candidates were then re-evaluated by absolute quantitative polymerase chain reaction analysis in an independent cohort of patients with PTC (n = 44) or benign nodules and 20 healthy controls (HCs). The 2 miRNAs most significantly associated with thyroid tumors were then assessed in matched serum samples (before and 30 days and 1 to 2 years after surgery) from the 20 PTC patients with complete follow-up datasets and results correlated

2017 Journal of the Endocrine Society

105. Final recommendation statement: thyroid cancer: screening.

Final recommendation statement: thyroid cancer: screening. Final recommendation statement: thyroid cancer: screening. | National Guideline Clearinghouse success fail JUN 10 2017 2018 2019 03 Oct 2017 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100 (...) Sign In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011212 2017 May NEATS Assessment Final recommendation statement: thyroid cancer: screening. Final recommendation statement: thyroid cancer: screening

2017 National Guideline Clearinghouse (partial archive)

106. Toxic thyroid adenoma

Toxic thyroid adenoma Toxic thyroid adenoma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Toxic thyroid adenoma Last reviewed: February 2019 Last updated: February 2019 Summary Typically a single large thyroid nodule accompanied by clinical and biochemical hyperthyroidism. Diagnosis confirmed by thyroid scan demonstrating a hot area and suppression of extranodular thyroid tissue. Hyperthyroidism caused by toxic (...) adenomas generally does not remit. Definitive treatment, such as radioactive iodine therapy, is usually required. Complications of untreated toxic adenomas may include sequelae of hyperthyroidism such as cardiac dysfunction or bone loss, or tracheal compression by large nodules. Definition A toxic adenoma is an autonomously functioning thyroid nodule that causes hyperthyroidism. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management

2017 BMJ Best Practice

107. Thyroid cancer

Thyroid cancer Thyroid cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Thyroid cancer Last reviewed: February 2019 Last updated: November 2017 Summary Most commonly presents as an asymptomatic thyroid nodule detected by palpation or ultrasound in a woman in her 30s or 40s. The most important diagnostic test is fine-needle aspiration. Treatment is usually total thyroidectomy followed by radioactive iodine (...) ablation and TSH suppression (papillary or follicular). Treatment differs and must be tailored for uncommon types of thyroid cancer such as medullary, lymphoma, or anaplastic. Prognosis depends on risk-group stratification. Definition Four types account for more than 98% of thyroid malignancies: papillary, follicular, anaplastic, and medullary. Gimm O. Thyroid cancer. Cancer Lett. 2001 Feb 26;163(2):143-56. http://www.ncbi.nlm.nih.gov/pubmed/11165748?tool=bestpractice.com History and exam presence

2017 BMJ Best Practice

110. Metastatic thyroid cancer - American Thyroid Association (ATA) guidelines

Metastatic thyroid cancer - American Thyroid Association (ATA) guidelines

2017 DynaMed Plus